Market Research Reports

Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

88pages
Published Date: 2014-01-20
 

Description


This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. These infections are not present in an individual before being admitted to hospital; instead the infections are developed after the admittance. Pathogens, primarily viral, bacterial and fungal are the main cause for the prevalence of nosocomial infections as they spread easily through the individual’s body and thereby deteriorate the immune system. The infections are mainly acquired from other patients, hospital staff, and contaminated objects, acting as potential vectors. Morbidity rate of nosocomial infections is increasing rapidly worldwide, hence driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. Therefore, the global hospital acquired disease testing market possesses tremendous growth potential, especially in the developing nations. 

This research report provides a detailed analysis of the global hospital acquired disease testing market and also aids in understanding the various driving factors for the growth of this market. The executive summary comprises the market snapshot which provides information about segments and sub-segments. The market overview section of the report demonstrates market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this market. Impact factors such as market attractiveness analysis and Porter’s five forces analysis of key market players have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the hospital acquired disease testing market. All these factors would help the market players to gain thorough analysis of the overall competitive scenario and thereby decide upon the business strategies and plans to be incurred in future for the global hospital acquired disease testing market. 

The global hospital acquired disease testing market is categorized on the basis of infection types and geography. The market estimates from 2011 to 2019 for each of these segments is provided in USD million. The global hospital acquired disease testing market, based on the type of infection is segmented into urinary tract infection (UTI) testing, surgical site infection(SSI) testing, pneumonia testing, blood stream infection (BSI) testing, methicillin-resistant staphylococcus aureus (MRSA) testing, and others (GI, bone, respiratory, cardiovascular, etc.). A detailed market analysis and forecast for these segments has been provided in this study in terms of market revenue (USD million) for the period 2011 to 2019. The report also provides the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2013 to 2019, while market size estimations have been made considering 2012 as the base year. 

Based on geography, the global hospital acquired disease testing market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the existing and new market players to sustain and grow in the global hospital acquired disease testing market. 

This report concludes with the company profiles section which includes key information such as company overview, financial overview, product portfolio, business strategies and recent developments about the major market players in hospital acquired disease testing market. Some of the key players profiled in this report include Diatherix Laboratories, Inc., Gen-Probe, Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.and others.

Table of Contents


Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Overview – Current Market Scenario and Future Market Trends
      3.1.1 Global Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
3.2 Drivers
      3.2.1 Establishment of Government Guidelines and Code of Prevention of HAIs
      3.2.2 Increasing Prevalence of HAIs and Rise in the Number of Drug Resistant Pathogens
      3.2.3 Expiration of Patents of Basic PCRs
3.3 Restraints
      3.3.1 Lack of Budget and Skilled Labour in Developing Countries
      3.3.2 Stringent Regulations and Guidance Framework
      3.3.3 Lack of Controlling Authorities and Control Programmes in Less Developed Regions
3.4 Opportunities
      3.4.1 Passing of the Patient Care and Affordable Care Act in the United States
      3.4.2 Technological Developments in the Field of Molecular Diagnostics
3.5 Porter’s Five Force Analysis for the Global Hospital Acquired Disease Testing Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of New Entrants
      3.5.4 Threat of Substitutes
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis of Global Hospital Acquired Disease Testing Market, by Geography

Chapter 4 Global Hospital Acquired Disease Testing, by Infection Type
4.1 Overview – Current Market Scenario and Future Market Trends
      4.1.1 Global Hospital Acquired Disease Testing Market, 2011 – 2019 (USD Million)
4.2 Urinary Tract Infection (UTI) Testing
      4.2.1 Global Urinary Tract Infection Testing Market Revenue, 2011 – 2019 (USD Million)
4.3 Surgical Site Infection (SSI) Testing
      4.3.1 Global Surgical Site Infection (SSI) Testing Market Revenue, 2011 - 2019  (USD Million)
4.4 Pneumonia Testing
      4.4.1 Global Pneumonia Testing Market Revenue, 2011 - 2019  (USD Million)
4.5 Blood Stream Infection (BSI) Testing
      4.5.1 Global Blood Stream Infection Testing Market Revenue, 2011 - 2019  (USD Million)
4.6 Methicillin-resistant Staphylococcus Aureus (MRSA) Testing
      4.6.1 Global Methicillin-resistant Staphylococcus Aureus (MRSA) Testing Market Revenue, 2011 - 2019  (USD Million)
4.7 Others (GI, Bone, Respiratory, Cardiovascular, Etc.)
      4.7.1 Global Other (GI, Joints, Respiratory, Cardiovascular, Etc.) Infections Testing Market Revenue, 2011 - 2019  (USD Million)
      4.7.2 Respiratory Infections
      4.7.3 Bone Infections
      4.7.4 Cardiovascular Infections
      4.7.5 Gastrointestinal Infections

Chapter 5 Global Hospital Acquired Disease Testing, by Geography
5.1 Overview – Current Market Scenario and Future Market Trends
      5.1.1 Global Hospital Acquired Disease Testing Market Revenue, by Geography, 2011-2019 (USD Million)
5.2 North America
      5.2.1 North America Hospital Acquired Disease Testing Market Revenue, 2011 - 2019 (USD Million)
      5.2.2 North America Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
5.3 Europe
      5.3.1 Europe Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)
      5.3.2 Europe Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)
      5.4.2 Asia-Pacific Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 Rest of the World (RoW) Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)
      5.5.2 RoW Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

Chapter 6 Recommendations
6.1 Educating and Training Hospital Staff
6.2 Focus on Expansion in Emerging Economies
6.3 Regulatory Compliance
6.4 Adapt to the Needs of Different Consumer Types

Chapter 7 Company Profiles
7.1 Abbott Laboratories, Inc.
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Business Strategies
      7.1.4 Recent Developments
7.2 Alere, Inc.
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Business Strategies
      7.2.4 Recent Developments
7.3 Becton, Dickinson and Company
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Business Strategies
      7.3.4 Recent Developments
7.4 bioMerieux, Inc.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Business Strategies
      7.4.4 Recent Developments
7.5 Cantel Medical Corporation
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Business Strategies
      7.5.4 Recent Developments
7.6 Cepheid, Inc.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Business Strategies
7.7 Diatherix Laboratories Inc.
      7.7.1 Company Overview
      7.7.2 Business Strategies
      7.7.3 Recent Developments
7.8 Gen-Probe, Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Business Strategies
      7.8.4 Recent Developments
7.9 F. Hoffman-La Roche, Ltd.
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Business Strategies
      7.9.4 Recent Developments
7.10 Life Technologies Corporation
      7.10.1 Company Overview
      7.10.2 Financial Overview
      7.10.3 Business Strategies
      7.10.4 Recent Developments
7.11 Meridian Bioscience, Inc.
      7.11.1 Company Overview
      7.11.2 Financial Overview
      7.11.3 Business Strategies
      7.11.4 Recent Developments
7.12 Nordion, Inc.
      7.12.1 Company Overview
      7.12.2 Financial Overview
      7.12.3 Business Strategies
      7.12.4 Recent Developments
7.13 Qiagen GmbH
      7.13.1 Company Overview
      7.13.2 Financial Overview
      7.13.3 Business Strategies
      7.13.4 Recent Developments

List of Figures

FIG. 1 Hospital Acquired Disease Testing: Market Segmentation
FIG. 2 Global Hospital Acquired Disease Testing Market Revenues, by Infection Type, 2012 (USD Million)
FIG. 3 Global Hospital Acquired Disease Testing Market Revenues, by Geography, 2012 (USD Million)
FIG. 4 Porter’s Five Force Analysis: Global Hospital Acquired Disease Testing Market
FIG. 5 Market Attractiveness Analysis of Global Hospital Acquired Disease Testing Market, by Geography
FIG. 6 Global Hospital Acquired Disease Testing Market, 2011 – 2019 (USD Million)
FIG. 7 Global Urinary Tract Infection Testing Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Surgical Site Infection (SSI) Testing Market Revenue, 2011 - 2019  (USD Million)
FIG. 9 Global Pneumonia Testing Market Revenue, 2011 - 2019  (USD Million)
FIG. 10 Global Blood Stream Infection Testing Market Revenue, 2011 - 2019  (USD Million)
FIG. 11 Global Methicillin-resistant Staphylococcus Aureus (MRSA) Testing Market Revenue, 2011 - 2019  (USD Million)
FIG. 12 Global Other (GI, Joints, Respiratory, Cardiovascular, Etc.) Infections Testing Market Revenue, 2011 - 2019  (USD Million)
FIG. 13 North America Hospital Acquired Disease Testing Market Revenue, 2011 - 2019 (USD Million)
FIG. 14 Europe Hospital Acquired Disease Testing Market Revenue, 2011 - 2019 (USD Million)
FIG. 15 Asia -Pacific Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)
FIG. 16 Rest of the World (RoW) Hospital Acquired Disease Testing Market Revenue, 2011 - 2019 (USD Million)
FIG. 17 Abbott Laboratories, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 18 Alere, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 19 Becton, Dickinson and Company.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 20 bioMerieux, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 21 Cantel Medical Corp.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 22 Cepheid, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 23 Gen-Probe, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 24 F. Hoffman-La Roche, Ltd.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 25 Life Technologies Corporation, Annual Revenue, 2010 – 2012 (USD Million)
FIG. 26 Meridian Bioscience, Inc.: Annual  Revenue, 2010 – 2012 (USD Million)
FIG. 27 Nordion, Inc.: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Hospital Acquired Disease Testing Market
TABLE 2 Global Hospital Acquired Disease Testing Market Revenues, by Infection Type, 2011 - 2019 (USD Million)
TABLE 3 Global Hospital Acquired Disease Testing Market Revenues, by Geography, 2011-2019 (USD Million)
TABLE 4 North America Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
TABLE 5 Europe Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
TABLE 6 Asia-Pacific Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)
TABLE 7 RoW Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

Enquiry Before Buying


Free Market Analysis


Nosocomial infections, most commonly called as hospital acquired diseases or healthcareassociated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infectionshas been observed worldwide and its morbidity rate is rapidly growing.Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptibleto nosocomial infection. Aging of population is one of the major factors thathas increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally. 

Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patientsas well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thuscreating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriatetreatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market.

Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus)infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections,leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall HAI testing market. 

In order to reduce the incidence rate of hospital acquired infections and the cost burden related to the same, governments in developed countries are increasingly trying to control and prevent the spread of nosocomial infections through several in-house and inspective initiatives. Developed countries such as United States, Canada, Australia and countries in Europe have governmental organizations that focus on control and prevention of HAIs in the respective country, e.g. Centers for Disease Control and Prevention (CDC) in the United States and National Health and Medical Research Council in Australia. These authorities have set a framework of rules and recommendations for healthcare organizations to manage each type of nosocomial infection.  Recommendations framed by these institutions give detailed description of which test is to be performed for the diagnosis of which type of infection. Various methods such as blood culture tests, quantitative PCR, latex agglutination test, wound culture and tissue biopsy are commonly performed for nosocomial infection diagnosis. HAI diagnostics market contributes 64% tothe overall molecular diagnostic market. Newer diagnostic tools have enabled reduced turnaround time and accurate diagnosis of the infection, driving the HAI testing market towards growth. 

Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia-Pacific is a lucrative market for HAI testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution of Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region.

global-hospital-acquired-disease-testing-market-revenue-by-infection-type-2012
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research